Additionally, APOE4 gene-edited iPSC-derived organoids have demonstrated distinct molecular and cellular alterations associated with this high-risk allele, further validating the role of APOE4 in AD pathogenesis and its utility in developing personalized therapies (Lin et al., 2018; Meyer et al., 2019). The gene discussed is APOE; the disease is Alzheimer disease.